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1. Introduction 
Joseph Stalin once said that one death is a tragedy but a million deaths is a statistic. Medical 
textbooks present percentages and p values, but medical professionals must deal with one 
death at a time. Textbooks are read in preparation for the profession. The purpose of this 
chapter is to bridge the gap by presenting an historical overview of the various 
controversies in the field of thyroid cancer that shaped our current knowledge and thereby 
assist the student in grasping the underlying structure beneath the vast amount of 
sometimes conflicting data.  
A student new to the arena may be surprised at finding the candy box assortment of colorful 
characters engaged in lively debate within the outwardly staid community. These people 
are passionate about the arcane details of thyroid carcinoma, a narrow specialty about 
which most students of medicine are indifferent. But the history of this field is fraught with 
debate, controversy, confrontations and a legacy of brave souls who dared to fight against 
the tide. 
The current opinions, as of 2011, regarding the treatment of differentiated thyroid cancer 
can roughly be divided into two groups, those that aggressively promote the adoption of 
total thyroidectomy with radioiodine ablation followed by periodic screening for 
biochemical recurrence and those that do not. The latter group usually prefers to perform 
thyroid lobectomy when the gross tumor is small and limited to one lobe of the thyroid, 
which would automatically rule out post-surgical ablation and the use of recombinant-TSH 
to screen for thyroglobulin. The option of lobectomy, although still resisted by many in the 
field, was finally adopted in the 2009 version of the guideline for the treatment of 
differentiated thyroid carcinoma by the American Thyroid Association1), but only for 
tumors measuring 10 millimeters or less. The following year, Sonkar et al2) wrote an article 
titled “Papillary Thyroid Carcinoma: Debate at Rest” writing that “the controversy 
regarding the extent of thyroidectomy in papillary thyroid carcinoma is relatively settled” 
with total thyroidectomy and radioiodine ablation being the preferred option for all but the 
smallest tumors. This announcement, however, proved premature. The 2010 version of the 
Japanese guideline for the treatment of thyroid tumors declared that papillary carcinomas as 
large as 30 millimeters were candidates for lobectomy when they were limited to one lobe of 
the thyroid with little or no extra-capsular invasion and gross lymph node involvement3). As 
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for papillary carcinoma less than 10 millimeters, some Japanese surgeons are proposing that 
observation without surgery may be sufficient4). The journey that lead to this schism and 
how it relates to the current therapeutic options is explained in this chapter as well as the 
most likely course that future therapy may take. 
2. The maverick 
Thyroid surgery was a dangerous endeavor in the 19th century and the French Academy of 
Medicine officially condemned the practice, but with the introduction of anesthesia, 
antisepsis techniques and hemostatic forceps, the prognosis improved dramatically. Billroth 
reported a mortality rate of 40% early in his career which fell to 8% in the 1870s5). Kocher 
reported a reduction in mortality from 12.6% to 0.2% from the 1870s to the end of the 19th 
century6). Successful thyroidectomy lead to the discovery of postoperative hypothyroidism 
which in turn elucidated the true function of the normal thyroid gland7). Klein reported on 
loss of voice due to injury to the recurrent laryngeal nerves during the removal of goiter8). 
Tetany was observed in patients who underwent total thyroidectomy, but it was only with 
the concerted efforts of multiple investigators around the turn of the century that damage to 
the parathyroid glands was found to be responsible for this condition9). Eventually, these 
discoveries lead to the reduction of surgical complications in thyroid surgery.  
Medical progress has advanced on a precarious balance between the pressing need for 
immediate solutions and the effort to keep harmful options out of the field. Pioneers of 
medicine made courageous, sometimes reckless, forays into uncharted territory to which we 
owe our current technology. But once the frontier was conquered and patient survival 
improved, more attention was paid to the tradeoffs of treatment, such as compromised 
quality of life, and efforts were made to diminish them. Surgery in particular has 
progressed, over the past half century, in the direction of reducing the extent of dissection 
and thereby lowering the risk of complications.  
George “Barney” Crile Jr. stands out as the man who set the field of surgery onto this 
course. Father of the celebrated journalist George Crile III and son of the venerated founding 
member of the Cleveland Clinic, George Crile Sr., he is something of an unsung hero of 
modern surgery. Surgery for thyroid carcinoma of his time, called the “block dissection” or 
“conventional radical neck dissection”, usually sacrificed the sternocleidomastoid muscle, 
often the accessory nerve and sometimes the inframandibular branch of the facial nerve. He 
wrote in 1957 “The deformities and dysfunctions which ensue are tragic consequences to 
teen-age girls and young women who are most commonly affected by papillary cancers of 
the thyroid. Loss of contour of the neck, paralysis of the muscles of the lower face, shoulder 
drop, later arthritic changes in the shoulder girdle, hoarseness from unilateral laryngeal 
nerve injuries, stridor from bilateral injuries, and tetany are serious and often permanent 
complications. The surgeon who inflicts them must be prepared to defend his position by 
incontrovertible proof of a higher rate of cure.”10) He argued that there was none. He was 
one of the first surgeons ever to promote the idea that “the less surgery the better”, and he 
campaigned vigorously for the abandonment of the classic block dissection. His ideas on 
thyroid cancer surgery, and later breast cancer surgery, were reluctantly but steadily 
adopted by the surgical community and have since shaped the evolution of surgical 
treatment.  
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It would be easier to compose a narrative if the history of thyroid surgery were a linear 
progression from “conventional radical neck dissection” to less and less invasive 
procedures. But the story is more muddled, partly due to the particular characteristics of the 
organ and also due to entrenched positions of opinionated surgeons and oncologists. The 
trajectory was also confounded by the periodic infusion of breathtaking new technology for 
which there was widespread but misguided enthusiasm. There was no consensus for the 
optimum surgical procedure for thyroid cancer surgery in the early to mid-twentieth 
century. If the gross tumor was limited to one lobe, some surgeons performed lobectomy, 
some lobectomy with isthmus, some lobectomy with isthmus and a part of the opposing 
lobe and some insisted on total thyroidectomy. A few even dared to perform partial 
lobectomy and preserved most of the thyroid. The extent of lymph node dissection also 
varied greatly11). Early on, metastasis to the lymph nodes in the neck were mistaken for 
embryological migration error termed “lateral aberrant thyroid” and believed not to require 
surgery. Conventional radical dissection may have been a backlash against this initial 
complacency12). 
During the time Crile was battling conventional radical dissection, others were arguing for 
more radical surgery. Clark et al performed serial sections of the whole thyroid. He found 
intraglandular dissemination in 58% of the 79 cases he studied13). Similar studies by Black et 
al found multicentricity in 20%14), and Underwood et al found contralateral lobe 
involvement in 32% of cases studied15). Each of these authors advocated total thyroidectomy 
or more based on their findings. However, Tollefsen, citing these works and others, 
compared them to the actual clinical recurrence rate in the opposite lobe. He pointed out 
that his recurrence rate was 3.7% and even Black, a proponent of radical surgery, had 
reported a recurrence in the opposite lobe in only 7%. In his 1963 report, Tollefsen wrote 
“The final importance of these histologic observations must rest in the clinical results. All 
but a small percentage of our patients have remained well for periods up to twenty-five 
years without clinical recurrence in the remaining lobe. We must, therefore, interpret these 
histologic cancers in the other lobe as being of slight importance and somewhat analogous 
to the autopsy incidence of microscopic cancer in the prostate.”16) It is surprising today to 
find that a surgeon in New York had already outlined the position taken by Japanese 
specialists of the twenty-first century half a century previously. Nobody today questions 
that papillary thyroid carcinoma is very often multi-focal, although some authors argue that 
microscopic multifocal disease is clinically irrelevant. 
3. Stratifications 
Care should be taken in reading, and especially in citing, medical reports of this era. 
Histologic classification and diagnosis did not follow the same criteria as we use today. 
Statistics were rudimentary and rarely employed anything more sophisticated than simple 
percentages. Most troublesome of all, such variables as the initial size of the pre-operative 
tumor or the age of the patient were not taken into account when discussing the merits of 
one surgical procedure over another. In 1953, Crile reported that patients aged over 40 at 
initial diagnosis had a poorer prognosis compared to patients aged under 40. He concluded 
“Since almost all cancers of the thyroid that occur in patients under 40 years of age are of the 
lowest grade malignancy, the prognosis in this age group is almost universally good if an 
adequate operation is performed”17). In his 1964 report Tollefsen analyzed 70 fatal cases of 
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papillary thyroid carcinoma and isolated age, initial size of tumor over 5 centimeters, 
recurrent laryngeal nerve palsy and distant metastasis as indicators of poor prognosis18). 
This was the beginning of the study of risk profiles in thyroid cancer. It was only after the 
prognostic indicators were clearly identified, and the outcome of treatment was compared 
among groups with equivalent risk profiles that the debate on surgical procedures rested on 
firm footing. Statistical techniques such as multivariate analysis were not employed in the 
study of thyroid cancer until the introduction of practical personal computers in the mid 
1980s. Nonetheless, “conventional radical neck dissection” fell out of favor by the early 
1970s. 
Meanwhile, a remarkable paradigm shift was surrounding the realm of thyroid surgery. The 
increasing acceptance of iodine prophylaxis markedly decreased the incidence of endemic 
goiter. Radioiodine and anti-thyroid drugs reduced the number of surgically treated Graves 
disease. Prior to the development of oral steroid medications, even subacute thyroiditis was 
often treated by surgery, but this method was completely abandoned. The practice of 
irradiating children for benign diseases, which apparently increased the incidence of 
radiation induced thyroid cancer, was no longer performed19). Core needle and fine needle 
biopsies made preoperative differentiation of benign and malignant tumors possible. Due to 
these developments and others, the number of thyroid operations performed in the 
Cleveland Clinic fell from 2,700 in the year 1927 to less than 50 in the late 1960s20). Thyroid 
cancer effectively became the last bastion of thyroid surgery. 
Imaging modalities also influenced surgery. In the late 1940s, ultrasonography was 
developed simultaneously in the United States, United Kingdom, Sweden and Japan. 
Although the earliest machines were cumbersome and impractical, the technology 
eventually improved to incorporate hand held probes which produced acceptably clear 
images. Fine needle aspiration biopsy was developed in the 1950s and eventually came into 
wide acceptance. But the combination of the two did not appear until the 1970s and was not 
widely used in the diagnosis of thyroid diseases until the 1980s. Computerized axial 
tomography was commercialized in the mid 1970s and magnetic resonance imaging in the 
early 80s, but neither machines were initially suitable for the examination of the neck area , 
CAT scan because of image artifacts from the bones and MRI (then called NMR-CT) because 
of low resolution. Both imaging technologies developed rapidly and became indispensable 
tools in the examination of the thyroid by the 1990s. The introduction of these diagnostic 
tools contributed greatly in the early detection of thyroid cancer and the incidence of 
thyroid cancer steadily increased21) while the size of tumor upon discovery steadily 
decreased after the mid 1980s3).  
Over the years, improvements in anesthesia made it safer for surgeons to take the time to 
carefully visualize the recurrent laryngeal nerve which was eventually proven to diminish 
the incidence of paralysis22). The same was true for the parathyroid, which when better 
preserved caused fewer cases of tetany. This meant that total thyroidectomy could be 
performed with smaller risk of surgical complications. 
So if the tumors were smaller but the complications were fewer, was it more logical to 
perform more conservative surgery or more radical surgery? Although this was not the 
question that was openly verbalized, this was the general area where the battle lines were 
drawn. And the debate was closely linked to the question of radioiodine therapy. 
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The use of radioactive isotope of iodine as a tracer for the thyroid was developed during the 
1930s and 40s. Eventually, this lead to the treatment of hyperthyroidism using 131-I23).  The 
experimental application of radioiodine on thyroid cancer began almost simultaneously24). It 
was soon established that replacement thyroid hormones should be withdrawn for the 
duration of this therapy and that healthy thyroid tissues need to be removed for this method 
to be effective. The use of thyroglobulin to screen for cancer recurrence was developed 
later25). It was then established that thyroglobulin measurements yield no useful information 
in the follow up of thyroid cancer patients in the presence of residual thyroid tissue26). Thus 
a new rationale for total thyroidectomy was introduced. Thyroid cancer patients would 
hence forth be given total thyroidectomy not because tumors were found in both lobes, but 
because it facilitated post-operative screening for recurrence and the treatment of recurrence 
should any be found. And not only were the thyroid removed surgically, but they were 
completely eradicated by means of “remnant ablation” using 131-I. 
Although some surgeons were initially skeptical about the utility of radioiodine therapy in 
the treatment of metastatic thyroid carcinoma, the contrarians were eventually silenced as 
data mounted supporting its efficacy. By the 1970s few argued against the adoption of 
radioiodine therapy, and consequently total thyroidectomy, on patients with proven distant 
metastasis. Routine remnant ablation and thyroglobulin screening, however, was a different 
matter. Once again, superiority of one regimen over the other was frequently argued 
without stratifying the cases according to various risk factors. In one example, Snyder 
pointed out in 1983 that the actual effectiveness of routine remnant ablation in reducing 
morbidity and mortality was not objectively proven due to this reason27). In a subsequent 
issue of the same journal, Riccabona published a letter to the editor which included a 
survival curve comparing the survival of patients who had undergone radioiodine ablation 
and patients who had not to show that radioiodine ablation indeed had a positive effect28). 
To this, Snyder replied that this was “yet another testimonial to what has plagued the 
evaluation of different approaches to the treatment of thyroid cancer patients” and asked 
“Were Dr. Riccabona’s patients randomized as to treatment? Were variables such as age, 
sex, histological type, histological grade, extent of disease, extent of surgery, and use of 
thyroid suppression therapy taken into account? What method was used in the detection of 
postoperative functioning tissue? Was ablation aimed at presumably normal thyroid tissue, 
or known residual thyroid cancer in the thyroid bed, or extrathyroidal functioning 
metastasis? Were these variables considered in the survival curve presented?” Few such 
dialogues were preserved in print, but similar debates occurred frequently in conferences 
around the world, occasionally accompanied by thunderous arguments and animated 
gesticulations, throughout the 1980s. Although not entirely as a consequence of such 
confrontations, the TNM staging system was introduced in 1987, AMES system in 1988, 
AGES system in 1987 and MACIS system in 1993. 
4. Debates 
Randomized prospective trials, had they been performed, may have helped settle many of 
the disputes. But differentiated thyroid carcinoma is an indolent cancer with a low rate of 
recurrence regardless of the treatment modality and often remains dormant for many years 
before tangible physical recurrence can be observed. This means that large numbers of 
patients would have to be followed for a very long time before a definite conclusion could 
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be reached. Thus, the studies on the optimum treatment for thyroid cancer would be left in 
the hands of prolific surgeons who would showcase their vast surgical experience in 
retrospective studies involving large numbers of patients. The field of thyroid cancer is 
littered with retrospective studies of hundreds, sometimes thousands of cases aimed at 
demonstrating the validity or otherwise of a given procedure. The extent of surgery is one of 
many controversial subjects that are so studied and there is a number of retrospective 
studies, properly stratified with AGES, AMES and pTNM, which demonstrate that total or 
near-total thyroidectomy reduces recurrence rates compared to lobectomy and similar 
unilateral resections29)30)31). What is often left unsaid is that patients who undergo near-total 
or total thyroidectomy must receive oral hormone replacement for a lifetime, while the 
majority of patients who undergo unilateral lobectomy remain euthyroid without 
medication. As a consequence, the patients who undergo lobectomy tend to have poor 
retention in retrospective studies because patients tend to stop visiting their doctors when 
they are feeling well. The difference in retention between patients of near-total or total 
thyroidectomy and patients of lobectomy is rarely ever mentioned in retrospective studies. 
But this helps explain why some investigators found no significant difference in recurrence 
between the two procedures32)33). 
And on top of all this was the professional bias of individual investigators. In the absence of a 
randomized trial, doctors generally do not perform treatments they do not believe in, due to 
which single-institution retrospective studies tend to have poorly structured control groups. 
Shiro Noguchi performed over ten thousand thyroid surgeries during his career by official 
record, not counting the thousands he hijacked while nominally assisting or overseeing them. 
He employed clerks whose sole mission was to stay in contact with his postoperative patients 
by telephone and mail, and to do detective work to track down their ever changing addresses. 
As a result, he published a number of long-term retrospective studies with large populations 
and excellent patient retention. His focus, however, was to prove the validity of prophylactic 
lymph node dissection. He called his procedure “modified radical neck dissection” even 
though nearly half of his cases involved only lobectomy. His belief was, if the lymph nodes of 
the neck were properly excised, neither total thyroidectomy nor remnant ablation were 
necessary in most low-to-moderate risk cases. His support of lobectomy was only secondary to 
his belief in prophylactic node dissection. Another prolific surgeon Orlo H. Clark, on the other 
hand, was a proponent of total thyroidectomy and remnant ablation who also happened to be 
skeptical about the value of prophylactic lymph node dissection. Naturally, Noguchi’s reports 
expounded on the merits of prophylactic node dissection, but compared results in the absence 
of remnant ablation. Clark’s reports stressed the merits of total thyroidectomy with remnant 
ablation in the absence of prophylactic node dissection. Clark’s arguments against 
prophylactic lymph node dissection rested on the assumption that the patient would receive 
remnant ablation. Noguchi did not employ radioiodine therapy in any of his cases with rare 
exceptions, low risk or otherwise, unless there was proven metastasis on image scans such as 
sonography, CAT, MRI or scintigraphy because he believed ablation was unnecessary and 
harmed the quality of life of his patients. Clark did not perform neck dissection unless there 
was proven metastasis on image scans for the same reason. Both surgeons reported excellent 
prognosis and low incidence of complications. (The two experts once joined hands to create a 
“definitive text” on thyroid cancer but the book, not surprisingly, was not a commercial 
success34).) As this example illustrates, each investigator had priorities among different points 
of controversy that made it difficult to compare the results of one report with another. 
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Other than the lack of prospective trials, varied patient retention, insufficient risk 
stratification and professional bias, there was also a linguistic problem. The idea that there is 
always some dissociation between the “signifier” and the “signified” is a relatively new 
concept that was not widely accepted among medical professionals of the previous 
generation. Authors almost never gave any thought to it. Noguchi’s use of the term 
“modified radical neck dissection” was just one example of many idiosyncrasies in the use 
of terminology that hampered understanding and obstructed progress. One of the more 
glaring examples was Mazzaferri’s use of the word “recurrence”. He frequently neglected to 
make the distinction between “recurrence” and “biochemical recurrence”35). In some cases, 
TSH stimulation produced positive thyroglobulin serum tests in the absence of tangible 
metastasis on image scans. Recurrence of thyroid cancer was only implied by serum data. 
Such cases were termed “biochemical recurrence”. The assumption was that these test 
results represented malignant recurrences too small to be visualized. When some doctors 
heard or read “recurrence” they automatically assumed that there was a detectable physical 
mass, but Mazzaferri was such an influential and widely cited authority that there would 
eventually be a school of specialists who used the term “recurrence” interchangeably with 
“biochemical recurrence”. It takes an astute reader to realize that the “recurrence rate” in 
one citation is not always the same thing as a “recurrence rate” in another. 
And then, in 1998, human recombinant TSH was approved for thyroglobulin testing. This 
was truly a product of advanced molecular biology and a cutting edge drug of a new era. It 
allowed testing for thyroglobulin without withdrawing replacement thyroid hormones. It 
would eventually be approved for use in radioiodine therapy, for which it had the same 
advantage. Unfortunately, the enthusiasm that this drug generated also provided incentive 
to perform total thyroidectomy where its necessity was still in question. 
Under the influence of these persistent obstacles, some researchers continued to hone their 
investigative strategies with ever more refined study designs. Others seemingly decided to 
take the kick-in-the-teeth approach. Ito et al performed an observational study of papillary 
microcarcinoma and found that only 15.9% increased in size beyond the margin of error 
(3mm or more) and only 3.4% presented novel nodal metastasis after 10 years of observation 
without treatment4). This finding was in line with the data from unsuspected 
microcarcinomas found in thyroids resected for other reasons36). If this is the malignant 
potential of clinically tangible tumors, the reasoning implied, what is the clinical significance 
of microscopic intragrandular focci or invisible biochemical recurrence? Granted that there 
is evidence that post-ablative serum thyroglobulin is a predictor of recurrence in low risk 
thyroid carcinoma37), an increasing number of studies suggest that routine ablation does not 
significantly suppress recurrence in low risk cases38)39). Some experts argue that remnant 
ablation should be performed anyway in order to prevent what little differentiated cancer 
that may remain from turning into anaplastic carcinoma, which is universally fatal. But the 
incidence of anaplastic carcinoma in North America where post-surgical ablation is 
performed routinely is substantially higher than the incidence in Japan where post-surgical 
ablation is still uncommon, although this difference has been attributed to the higher iodine 
content of the Japanese diet40).  
Authors on both sides of the debate have pointed out that not all papillary carcinomas are 
equally indolent. Some grow rapidly and progress more aggressively than others without 
obvious histological differences. Histological variations such as tall cell variants and 
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columnar cell variants have been identified41)42), but many unusually malignant strains 
cannot be morphologically identified as any different from other examples of papillary 
carcinoma. How to identify the rare differentiated cancers that are most likely to take a more 
malignant course is an important and unanswered question. Clinical risk factors are 
currently the only guide, although some studies on molecular prognostic markers are being 
performed43)44). 
Proponents of lobectomy point out that only one recurrent laryngeal nerve is at risk when 
only one lobe of the thyroid is being resected thus the theoretical risk of nerve palsy is 
halved45). Proponents of total thyroidectomy insist that the increase in complications is 
minimal at the hands of an experienced surgeon46). Disagreement over the merits of 
prophylactic central node dissection is argued along similar lines47)48)49). Experience suggests 
that the incidence of surgical complications is much more dependent on the proficiency of 
the surgeon than the type of surgery performed. Experts who are experienced enough to 
publish large retrospective studies invariably report excellent results regardless of the type 
of surgery they promote. 
5. Where we are 
So which is the better option? Is it more practical to allow a small number of recurrences and 
re-operate on those that recur, or ablate at the first sign of a biochemical recurrence and risk 
salivary gland damage to prevent re-operation? Is it more economical to periodically check 
for thyroglobulin with recombinant TSH, or just follow with sonogram and surgically 
remove the metastasis when they appear? The cost of surgery, radioiodine therapy, image 
scans and cytology tests vary tremendously in the US, Europe and Japan, to say nothing of 
the availability of high end care, the social costs of hospitalization, the geographic distance 
to specialized institutions and the medical legal demands on the doctor. Depending on the 
location of the patient and the local cost structure of medical care, one option may be more 
advantageous than another. At the bottom line, the current argument on low risk thyroid 
cancer is whether or not it is an acceptable tradeoff to allow a minimally increased risk of 
surgical complications to guard against a minimally increased risk of cancer recurrence 
when there is no proven difference in prognosis. It is difficult to reach a conclusion because 
the difference in benefits and demerits are so small, the choice is largely dependent on the 
preference and socio-economic situation of the patient. Perhaps it is time for this debate to 
leave the ivory tower and be presented to the patients who are directly affected. 
The experts now nearing retirement or who have retired in the past few decades have lived 
through a vibrant age. Long ago, in an American hospital, two reputable surgeons with 
conflicting surgical philosophy had an argument in the operating room when, after the 
initial incision, they found the extent of disease to be not what they expected. Anesthesia 
was not as stable then as it is today and time was precious. In exasperation, one surgeon 
punched the other in the face, calmly changed his gloves, and completed the surgery alone 
while the other lay unconscious on the operating room floor. Such buccaneering days have 
long since ended. The controversies surrounding thyroid cancer today do not have the 
consequences of Crile’s time when he started his crusade against radical thyroidectomy and 
radical mastectomy. This is an inevitable result of medical progress. As the prognosis 
improves and complications diminish, the persisting debates become increasingly pedantic. 
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Today there are surgical conferences around the world that no longer hold independent 
sessions for the discussion of thyroid cancer surgery. As sobering as it may sound, fading 
from attention is the final reward of great medical progress. We cannot be disappointed that 
the scope of our arguments has become smaller. Our patients are better for it. 
If the past is any guide, the future of thyroid cancer treatment will most likely evolve in two 
major directions. One is the treatment of poorly differentiated and unresponsive cancers. 
The other is the ever earlier diagnosis and increasingly conservative treatment of low 
malignancy cancers. Endoscopic and robotic surgery that are seeing wider application in the 
gastroenterological field are being tested in thyroid surgery. Laser ablation and radio 
frequency ablation, both of which use specialized needles inserted percutaneously to ablate 
benign thyroid nodules, are also being tested on a limited sub-group of malignant 
tumors50)51). If more evidence is accumulated that low-risk papillary cancers are as indolent 
as some researchers claim, such low invasion techniques may see wider application. The 
current debate on the choice between total thyroidectomy and lobectomy may seem quaint 
when, in the future, microcarcinomas are treated with needles tipped with thermal 
coagulation devises.  
Conservative surgery became possible in other fields of oncology partly due to the 
development of adjuvant chemotherapy. Though conventional chemotherapy is not 
effective for differentiated thyroid cancer, tyrosine kinase inhibitors hold some promise. 
This new class of drugs is being tested, with encouraging results, on radioiodine refractory 
cases52), medullary carcinoma53) and anaplastic carcinoma54). Combination therapy in the 
future may produce even better results.  
Molecular biology has enhanced our understanding of thyroid cancer greatly. Genetic 
testing has allowed for early detection of MEN type 2 and prophylactic thyroidectomy55). 
Tyrosine kinase inhibitors, histone deacetylase inhibitors56) and nijmegen breakage 
syndromes57) are being studied as potential new therapies for anaplastic carcinoma. Studies 
of micro-RNAs have provided some interesting hints in their potential for diagnosis and 
treatment of cancer58). Further studies may present more focused differentiation of low-risk 
and high-risk cancers on the molecular level. 
6. Summary 
In summary, much has been elucidated about thyroid cancer in the past century and a half. 
We owe our current expertise to those who dared to challenge the status quo. The general 
direction of the evolution of thyroid cancer treatment has been toward lesser invasion and 
increasingly tailored therapy as we learned to more correctly differentiate low-risk from 
high-risk and acquired knowledge and confidence to leave well enough alone. The future 
will most likely follow this trend, differentiating the risk categories with ever greater 
accuracy and treating them with increasingly focused therapy. Trends to the contrary are 
likely to be momentary aberrations or corrections to the course. As prognosis improves and 
complications diminish, points of controversy in treatment options will be of increasingly 
smaller universal significance and will inevitably invite greater patient involvement in 
clinical decision making. There are still frontiers to be conquered in the field of thyroid 
cancer, though not as wild or lawless as in the past. There will always be room for 
innovators in the future. One only needs to proceed in the right direction.  
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(The author is a fourth generation thyroidologist. The Noguchi Thyroid Clinic and Hospital 
Foundation celebrates its 90th anniversary in 2012.) 
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